Alzheimer's Association International Conference (AAIC) 2022 | July 31 - August 4
August 3, 2022 – Moebius
Phase II Drug Development for Alzheimer’s Disease Panel Presentation: Athira Pharma
August 2, 2022 – Reda et al.
Fosgonimeton, a Novel, Small-Molecule Positive Modulator of the HGF/MET System, is Neuroprotective in Primary Neuron Culture
July 31, 2022 – Taylor et al.
Development of Stable, Orally Bioavailable, Small-Molecule Positive Modulators of HGF/MET Signaling for the Treatment of Cognitive Impairment
August 3, 2022 – Moebius et al.
ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial